Quantification of muscle strength and motor ability in patients with duchenne muscular dystrophy on steroid therapy

Arquivos de Neuro-Psiquiatria

Volumn 65, Issue 2 A, 2007, Pages 245-250

  Parreira, Samara Lamounier Santana ^a,b   Resende, Maria Bernadete Dutra ^a   Peduto, Marília Della Corte ^a   Marie, Suely Kazue Nagahashi ^a   Carvalho, Mary Souza ^a   Reed, Umbertina Conti ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b NONE   (Brazil)

Author keywords

Corticosteroids; Duchenne muscular dystrophy; Hammersmith motor ability score; Motor ability; MRC scale; Muscle strength

Indexed keywords

DEFLAZACORT; PREDNISOLONE;

ARTICLE; CHILD; CLINICAL ARTICLE; DUCHENNE MUSCULAR DYSTROPHY; HUMAN; MOTOR PERFORMANCE; MUSCLE STRENGTH; PATIENT ASSESSMENT; SINGLE DRUG DOSE;

EID: 34347357667     PISSN: 0004282X     EISSN: 16784227     Source Type: Journal    
DOI: 10.1590/s0004-282x2007000200011     Document Type: Article

References (28)

1. Scott OM, Goddard C, Dubowitz V. Quantitation of muscle function in children: a prospective study in Duchenne muscular dystrophy. Muscle Nerve 1982;5:291-301.
2. Angelini C, Pegoraro E, Turella E, Intino M, Pini A, Costa C. Deflazacort in Duchenne dystrophy: study of long-term effect. Muscle Nerve 1994;17:386-391.
3. Backman E, Henriksson G. Low-dose prednisolone treatment in Duchenne and Becker muscular dystrophy. Neuromusc Disord 1995;5:233-241.
4. Biggar WD, Gingas M, Flebings DL, Harris VA, Steele CA. Deflazacort treatment of Duchenne muscular dystrophy. J Ped 2001;138:45-50.
5. Biggar WD, Politano L, Harris VA, et al. Deflazacort in Duchenne muscular dystrophy: a comparison of two different protocols. Neuromusc Disord 2004;14:476-482.
6. Bonifati MD, Ruzza G, Bonometto P, et al. A multicenter, double-blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy. Muscle Nerve 2000;23:1344-1347.
7. Brooke M, Fenichel GM, Griggs RC. Clinical investigation in Duchenne dystrophy: 2. Determination of the "power" of therapeutic trials basead on the natural history. Muscle Nerve 1983;6:91-103.
8. Brooke MH, Griggs RC, Mendell JR. Clinical trial in Duchenne dystrophy. The design of the protocol. Muscle Nerve 1981;4:186-197.
9. th ENMC International Workshop. Treatment of Duchenne muscular dystrophy; defining the gold standards of management in the use of corticosteroids. 2-4 April 2004, Naarden, The Netherlands. Neuromuscul Disord 2004;14:526-534.
10. Carter GT, McDonald CM. Preserving function in Duchenne muscular with long-term pulse prednisone therapy. Am J Phys Med Rehabil 2000;78:455-458.
11. Connolly A, Schierbecker J, Renna R, Florence J. High dose weekley oral prednisone improve strength in boys with Duchenne muscular dystrophy. Neuromuscul Disord 2002;12:917-925.
12. Silva S, Drachman DB, Mellits D, Kunel W. Prednisone treatment in Duchenne muscular dystrophy. Arch Neurol 1987;4:818-822.
13. Drachman DB, Toyka KV. Prednisone in Duchenne muscular dystrophy. Lancet 1974,14:1409-1412.
14. Dubowitz V, Kinali M, Main M, Mercur E, Muntoni F. Remission of clinical signs in early Duchenne muscular dystrophy on intermittent low-dosage prednisolone therapy. Neuromusc Disord 2002;6:53-59.
15. Fenichel GM, Florence JM, Pestronk A, et al. Long-term benefit from prednisone therapy in Duchenne muscular dystrophy. Neurology 1991;41:1874-1877.
16. Griggs RC, Moxley RT, Mendell JR, et al. Duchenne distrophy: randomized controlled trial of prednisone (18 months) and azathioprine. Neurology 1993;93:520-527.
17. Griggs RC, Moxley RT, Mendell JR, et al. Prednisone in Duchenne dystrophy: a randomized, controlled trial defining the time course and response. Arch Neurol 1991;48:383-388.
18. Kinali M, Mercuri E, Main M, Muntoni F, Dubowitz V. The effective low dosage intermittent schedule of prednisone in the long-term treatment of early cases of Duchenne muscular dystrophy. Neuromusc Disord 2002;12:169-174.
19. Mendell JR, Moxley RT, Griggs RC. Randomized double-blind six month trial of prednisone in Duchenne muscular dystrophy. N Engl J Med 1989;320:1592-1597.
20. Merlini L, Cicognani A, Malaspina E, et al. Early prednisone treatment in Duchenne muscular dystrophy. Muscle Nerve 2003;27:222-227.
21. Muntoni F, Fisher I, Jennifer EM, Abraham D. Steroids in Duchenne muscular dystrophy from clinical trials to genoma research. Neurom Disord 2002;12:162-165.
22. Shara U, Mortier J†, Mortier W. Long-term steroid therapy in Duchenne muscular dystropy: positive versus side effects. J Clin Neuromusc Dis 2001;2:179-183.
23. Leitão AVNA. Avaliação funcional e medidas de parâmetros lineares e tempo espaciais da marcha na distrofia muscular progressiva: forma clínica de Duchenne. Dissertação. Rio de Janeiro, 1997.
24. Medical Research Council. Aids to the investigation of peripheral nerve injuries. London, England: Her Majesty's Stationery Office, 1976.
25. Johnson EW. Pathokinesiology of Duchenne muscular dystrophy: implications for management. Arch Phys Med Rehabil 1977;58:4-7.
26. Sutherland DH, Olshen R. The pathomechanics of gait in Duchenne muscular dystrofy. Develop Med Child Neurol 1981;23:3-22.
27. Perry JK. Gait analysis systems: normal and pathological function. Thorofare, NJ: USA. Slack. 1992:542:9-38/294-299/353-411.
28. Fenichel JM. Prolongation of ambulation in children with Duchenne muscular distrofy by subcutaneous lower limb tenotomy. J Ped Orthopaed 1993;13:336-340.